Daewoong Co., Ltd.

A003090

KR7003090008

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
18,820 ^KRW	+0.64%		+3.75%	-8.86%

Apr. 24	Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	MT
Mar. 08	Daewoong Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tranche Update on Daewoong Co., Ltd.'s Equity Buyback Plan announced on July 27, 2023.

January 31, 2024 at 02:39 am EST

From October 1, 2023 to December 31, 2023, the company has repurchased 85,630 shares, representing 0.21% for KRW 1,443.95 million. With this, the company has completed the repurchase of 690,630 shares, representing 1.66% for KRW 9,997.24 million under the buyback announced on July 27, 2023.

Latest news about Daewoong Co., Ltd.

Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	Apr. 24	MT
Daewoong Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Daewoong Pharmaceutical Secures Approval for Stem Cell Processing Facility in Indonesia	Feb. 15	MT
Tranche Update on Daewoong Co., Ltd.'s Equity Buyback Plan announced on July 27, 2023.	Feb. 05	CI
Tranche Update on Daewoong Co., Ltd.'s Equity Buyback Plan announced on July 27, 2023.	Jan. 31	CI
Daewoong Co., Ltd.'s Equity Buyback announced on July 27, 2023, has closed with 690,630 shares, representing 1.66% for KRW 9,997.24 million.	Jan. 30	CI
Zydus Unit, Daewoong Pharma to Co-Develop, Commercialize Leuprolide Acetate in US	Dec. 11	MT
Daewoong Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Tranche Update on Daewoong Co., Ltd.'s Equity Buyback Plan announced on July 27, 2023.	Nov. 03	CI
Hyphens Pharma Unit to Distribute Daewoong Pharmaceutical's Nabota Botox in Malaysia	23-08-30	MT
Daewoong Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Daewoong Pharmaceutical's Nabota Surpasses 600,000 Customers in the US	23-08-02	MT
Daewoong Co., Ltd. announces an Equity Buyback for KRW 10,000 million worth of its shares.	23-07-27	CI
Daewoong Co., Ltd. authorizes a Buyback Plan.	23-07-26	CI
Avacta sees shares rise on new equity payment for South Korea venture	23-06-05	AN
Daewoong Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Daewoong Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-08	CI
An Unknown buyer completed the acquisition of 66.2% stake in Palmpack Co., Ltd. from Daewoong Co., Ltd..	23-02-27	CI
Sonoma Pharmaceuticals Signs Distribution Deal With Daewoong Pharmaceutical to Sell Skin Products in South Korea	23-01-31	MT
Oncorus, Daewoong Pharmaceutical to Develop Lipid Nanoparticle Formulations for mRNA Drug Candidate; Shares Surge	23-01-04	MT
Daewoong Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Daewoong Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
Daewoong Pharmaceutical Aims to Expand Reach of Nabota Beyond Cosmetic Applications	22-05-30	MT
Avacta JV Extends Drug Manufacturing Agreement With GenScript	22-05-16	MT
Daewoong Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI

Chart Daewoong Co., Ltd.

Duration

Period

More charts

Company Profile

Daewoong Co Ltd is a Korea-based holding company engaged in the manufacture and sale of pharmaceuticals. The Company operates its business mainly through subsidiaries including Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd, Daewoong Development Co Ltd, and Hanall Biopharma Co Ltd. Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd and Hanall Biopharma Co Ltd are engaged in the manufacture and sale of pharmaceuticals. Daewoong Development Co Ltd is engaged in real estate rental and supply business. In addition, IDS&Trust Co Ltd manufactures and sells communication-related devices. Daewoong Life Science Co Ltd is engaged in food processing and sales. Pampaeg Co Ltd is engaged in the packaging business of quasi-drugs. Daewoong Management Development Institute Co Ltd is engaged in management and industrial training projects.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Daewoong Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

18,820 KRW

Average target price

25,000 KRW

Spread / Average Target

+32.84%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
DAEWOONG CO., LTD.	-8.86%	556M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.27%	43.75B
OTSUKA HOLDINGS CO., LTD.	+27.47%	22.06B
SANDOZ GROUP AG	+15.11%	14.46B
CIPLA LIMITED	+12.33%	13.62B
ZYDUS LIFESCIENCES LIMITED	+38.36%	11.61B
ONO PHARMACEUTICAL CO., LTD.	-9.54%	6.9B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+10.21%	5.32B

Generic Pharmaceuticals

Daewoong Co., Ltd.

Equities

A003090

KR7003090008

Pharmaceuticals

Tranche Update on Daewoong Co., Ltd.'s Equity Buyback Plan announced on July 27, 2023.

Latest news about Daewoong Co., Ltd.

Chart Daewoong Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Daewoong Co., Ltd.

Analysts' Consensus

Annual profits - Rate of surprise

Sector Generic Pharmaceuticals